Skip to main content
. 2017 May 2;8(31):51037–51049. doi: 10.18632/oncotarget.17558

Figure 3. Construction and characterization of anti-HER2 bsAb KN026.

Figure 3

(A) Schematic drawing of the bsAb KN026. (B) Thermal stability of KN026 was examined by differential scanning calorimetry (DSC). (C) Binding affinity of KN026, trastuzumab (Tmab) and pertuzumab (Pmab) against dual antigens was determined by sandwich ELISA. (D) The binding affinity assessment of KN026, trastuzumab (Tmab) and pertuzumab (Pmab) to HER2 on human cancer cells (BT474, NCI-N87, Calu-3).